Omnitrope Hiccup: How Not To File For Biogeneric Approval in Europe
Sandoz's Omnitrop was expected to become the first marketed biogeneric in Europe, following a positive CPMP recommendation last June. But in March 2004 it emerged that the European Commission, in an unusual move, had blocked the drug's approval late last year. While certainly a setback for Sandoz, and hardly comforting to the rest of the sector, the events appear to result from a misunderstanding over the legal basis of the application, rather than from any deeper reluctance among European lawmakers to approve biosimilar products.
You may also be interested in...
In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.
European regulators’ guidelines on biosimilars show that they are serious about quickly approving cheaper follow-on biologics. The hurdles may come thereafter.
Buying Hexal shows Novartis' commitment to generics. The Swiss group also hopes the move will bring more credibility, and better deals, across all of its businesses.